MBIO Mustang Bio Inc.

4.4
+0.37  (+9%)
Previous Close 4.03
Open 4.2
Price To Book 2.67
Market Cap 119959976
Shares 27,263,631
Volume 42,513
Short Ratio
Av. Daily Volume 83,609

SEC filingsSee all SEC filings

  1. 8-K - Current report 181179684
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181177988
  3. 8-K - Current report 181012522
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181012318
  5. EFFECT - Notice of Effectiveness 18975984

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1/2 trial to be initiated 4Q 2017.
CD20 Technology
Relapsed or refractory B-cell non-Hodgkin lymphomas
Phase 1 ongoing with Phase 1/2 trial to be initiated 2019.
MB-102
Acute myeloid leukemia
Phase 1 trial recruiting.
MB-101
Glioblastoma
Phase 1 trial initiation announced October 30, 2018.
CAR-T therapy
HER2-positive breast cancer

SEC Filings

  1. 8-K - Current report 181179684
  2. 10-Q - Quarterly report [Sections 13 or 15(d)] 181177988
  3. 8-K - Current report 181012522
  4. 10-Q - Quarterly report [Sections 13 or 15(d)] 181012318
  5. EFFECT - Notice of Effectiveness 18975984
  6. 8-K - Current report 18975479
  7. 424B5 - Prospectus [Rule 424(b)(5)] 18975465
  8. CORRESP [Cover] - Correspondence
  9. CORRESP [Cover] - Correspondence
  10. S-3/A [Amend] - Registration statement under Securities Act of 1933 18962998